A 60-year-old female with post-concussion syndrome (PCS) presented with persistent cognitive deficits and functional limitations following a slip and fall. She underwent a multimodal therapeutic protocol including hyp...A 60-year-old female with post-concussion syndrome (PCS) presented with persistent cognitive deficits and functional limitations following a slip and fall. She underwent a multimodal therapeutic protocol including hyperbaric therapy (HBT), photobiomodulation (PBM), and molecular hydrogen (MH) therapy over 10 sessions. Pre- and post-treatment assessments demonstrated significant improvements in cognitive function and neurophysiological markers, as evidenced by WAVi EEG and Trail Making Test (TMT) results. This case highlights the potential of a non-invasive, multimodal therapeutic approach to address persistent post-concussion symptoms, an area with limited effective interventions. Findings suggest that integrating these therapies into standard rehabilitation protocols may enhance recovery trajectories, particularly for patients with persistent cognitive symptoms. This case report explores the clinical course, treatment efficacy, and the potential for combining these therapies in addressing complex neurological recovery.展开更多
This case report examines the impact of mild hyperbaric oxygen therapy (mHBOT) on cognitive function and symptom relief in a 35-year-old male presenting with concussive symptoms (CS) following a motor vehicle accident...This case report examines the impact of mild hyperbaric oxygen therapy (mHBOT) on cognitive function and symptom relief in a 35-year-old male presenting with concussive symptoms (CS) following a motor vehicle accident (MVA). The patient underwent 10 mHBOT sessions over five weeks (40 minutes per session at 1.5 ATA with 32% oxygen). Post-treatment assessments revealed significant improvements, including an increase in P300 voltage from 4.2 µV to 9.2 µV, aligning with the normative range of 8 - 21 µV. Electroencephalogram (EEG) analysis demonstrated enhanced alpha and theta band activity, reflecting improved cognitive processing and attentional regulation. Clinically, the patient reported reduced headache severity, improved sleep quality, and decreased pain intensity. These findings suggest that mHBOT may support neuroplasticity, mitigate inflammation, and restore cognitive function in patients with CS. Further research, including randomized controlled trials (RCTs), is warranted to validate mHBOT’s efficacy and explore its long-term benefits in traumatic brain injury (TBI) rehabilitation.展开更多
Brain functional impairment after stroke is common;however,the molecular mechanisms of post-stroke recovery remain unclear.It is well-recognized that age is the most important independent predictor of poor outcomes af...Brain functional impairment after stroke is common;however,the molecular mechanisms of post-stroke recovery remain unclear.It is well-recognized that age is the most important independent predictor of poor outcomes after stroke as older patients show poorer functional outcomes following stroke.Mounting evidence suggests that axonal regeneration and angiogenesis,the major forms of brain plasticity responsible for post-stroke recovery,diminished with advanced age.Previous studies suggest that Ras-related C3 botulinum toxin substrate(Rac)1 enhances stroke recovery as activation of Rac1 improved behavior recovery in a young mice stroke model.Here,we investigated the role of Rac1 signaling in long-term functional recovery and brain plasticity in an aged(male,18 to 22 months old C57BL/6J)brain after ischemic stroke.We found that as mice aged,Rac1 expression declined in the brain.Delayed overexpression of Rac1,using lentivirus encoding Rac1 injected day 1 after ischemic stroke,promoted cognitive(assessed using novel object recognition test)and sensorimotor(assessed using adhesive removal tests)recovery on days 14–28.This was accompanied by the increase of neurite and proliferative endothelial cells in the periinfarct zone assessed by immunostaining.In a reverse approach,pharmacological inhibition of Rac1 by intraperitoneal injection of Rac1 inhibitor NSC23766 for 14 successive days after ischemic stroke worsened the outcome with the reduction of neurite and proliferative endothelial cells.Furthermore,Rac1 inhibition reduced the activation of p21-activated kinase 1,the protein level of brain-derived neurotrophic factor,and increased the protein level of glial fibrillary acidic protein in the ischemic brain on day 28 after stroke.Our work provided insight into the mechanisms behind the diminished plasticity after cerebral ischemia in aged brains and identified Rac1 as a potential therapeutic target for improving functional recovery in the older adults after stroke.展开更多
文摘A 60-year-old female with post-concussion syndrome (PCS) presented with persistent cognitive deficits and functional limitations following a slip and fall. She underwent a multimodal therapeutic protocol including hyperbaric therapy (HBT), photobiomodulation (PBM), and molecular hydrogen (MH) therapy over 10 sessions. Pre- and post-treatment assessments demonstrated significant improvements in cognitive function and neurophysiological markers, as evidenced by WAVi EEG and Trail Making Test (TMT) results. This case highlights the potential of a non-invasive, multimodal therapeutic approach to address persistent post-concussion symptoms, an area with limited effective interventions. Findings suggest that integrating these therapies into standard rehabilitation protocols may enhance recovery trajectories, particularly for patients with persistent cognitive symptoms. This case report explores the clinical course, treatment efficacy, and the potential for combining these therapies in addressing complex neurological recovery.
文摘This case report examines the impact of mild hyperbaric oxygen therapy (mHBOT) on cognitive function and symptom relief in a 35-year-old male presenting with concussive symptoms (CS) following a motor vehicle accident (MVA). The patient underwent 10 mHBOT sessions over five weeks (40 minutes per session at 1.5 ATA with 32% oxygen). Post-treatment assessments revealed significant improvements, including an increase in P300 voltage from 4.2 µV to 9.2 µV, aligning with the normative range of 8 - 21 µV. Electroencephalogram (EEG) analysis demonstrated enhanced alpha and theta band activity, reflecting improved cognitive processing and attentional regulation. Clinically, the patient reported reduced headache severity, improved sleep quality, and decreased pain intensity. These findings suggest that mHBOT may support neuroplasticity, mitigate inflammation, and restore cognitive function in patients with CS. Further research, including randomized controlled trials (RCTs), is warranted to validate mHBOT’s efficacy and explore its long-term benefits in traumatic brain injury (TBI) rehabilitation.
基金supported by NIH grants RF1 AG069466(to JL and LDM),R01 NS099628(to JL),and AG069466(to JL and LDM)the American Heart Association award 20POST35180172(to FB)。
文摘Brain functional impairment after stroke is common;however,the molecular mechanisms of post-stroke recovery remain unclear.It is well-recognized that age is the most important independent predictor of poor outcomes after stroke as older patients show poorer functional outcomes following stroke.Mounting evidence suggests that axonal regeneration and angiogenesis,the major forms of brain plasticity responsible for post-stroke recovery,diminished with advanced age.Previous studies suggest that Ras-related C3 botulinum toxin substrate(Rac)1 enhances stroke recovery as activation of Rac1 improved behavior recovery in a young mice stroke model.Here,we investigated the role of Rac1 signaling in long-term functional recovery and brain plasticity in an aged(male,18 to 22 months old C57BL/6J)brain after ischemic stroke.We found that as mice aged,Rac1 expression declined in the brain.Delayed overexpression of Rac1,using lentivirus encoding Rac1 injected day 1 after ischemic stroke,promoted cognitive(assessed using novel object recognition test)and sensorimotor(assessed using adhesive removal tests)recovery on days 14–28.This was accompanied by the increase of neurite and proliferative endothelial cells in the periinfarct zone assessed by immunostaining.In a reverse approach,pharmacological inhibition of Rac1 by intraperitoneal injection of Rac1 inhibitor NSC23766 for 14 successive days after ischemic stroke worsened the outcome with the reduction of neurite and proliferative endothelial cells.Furthermore,Rac1 inhibition reduced the activation of p21-activated kinase 1,the protein level of brain-derived neurotrophic factor,and increased the protein level of glial fibrillary acidic protein in the ischemic brain on day 28 after stroke.Our work provided insight into the mechanisms behind the diminished plasticity after cerebral ischemia in aged brains and identified Rac1 as a potential therapeutic target for improving functional recovery in the older adults after stroke.
